Status
Conditions
Treatments
About
This is a prospective parallel group, double-blinded randomized controlled trial. Subjects are randomized into two groups - the intervention group and waitlist control group. Subjects received resistance, aerobic, flexibility and balance exercise training; and nutritional supplement containing β-hydroxy β-methylbutyrate (HMB). The intervention group would first receive the intervention during the 12-week study period. Meanwhile, the waitlist control group would receive 12 weeks of conventional care. After the study period, they would receive the same intervention.
Enrollment
Sex
Volunteers
Inclusion criteria
Diagnosis of sarcopenia:
Diagnosed with osteoporosis by:
Exclusion criteria
Incompetent in giving consent or following commands
Non-ambulatory subject
Unstable medical conditions contributing to sarcopenia, for example but not limited to:
Chronic kidney disease stage IV or above or with hyperkalaemia
Diabetes mellitus on medications or with unstable control
Terminal illness
Obese subjects (BMI ≥ 25.0)
Self-reported allergy to the ingredients of the nutrition supplement
Patients with metallic implants
Any orthopaedic pathologies affecting the strength of bilateral upper limbs
Any hereditary or acquired muscular diseases
Participation in other regular exercise programme
Primary purpose
Allocation
Interventional model
Masking
13 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal